The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The evolution of brachytherapy for prostate cancer
Open accessAbstract
Brachytherapy (BT), using low-dose-rate (LDR) permanent seed implantation or high-dose-rate (HDR) temporary source implantation, is an acceptable treatment option for select patients with prostate cancer of any risk group. The benefits of HDR-BT over LDR-BT include the ability to use the same source for other cancers, lower operator dependence, and — typically — fewer acute irritative symptoms. By contrast, the benefits of LDR-BT include more favourable scheduling logistics, lower initial capital equipment costs, no need for a shielded room, completion in a single implant, and more robust data from clinical trials. Prospective reports comparing HDR-BT and LDR-BT to each other or to other treatment options (such as external beam radiotherapy (EBRT) or surgery) suggest similar outcomes. The 5-year freedom from biochemical failure rates for patients with low-risk, intermediate-risk, and high-risk disease are >85%, 69–97%, and 63–80%, respectively. Brachytherapy with EBRT (versus brachytherapy alone) is an appropriate approach in select patients with intermediate-risk and high-risk disease. The 10-year rates of overall survival, distant metastasis, and cancer-specific mortality are >85%, <10%, and <5%, respectively. Grade 3–4 toxicities associated with HDR-BT and LDR-BT are rare, at <4% in most series, and quality of life is improved in patients who receive brachytherapy compared with those who undergo surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, R. C., Riley, A., Wagner, G., Osterloh, I. H., Kirkpatrick, J., & Mishra, A. (1997) · Urology · doi:10.1016/s0090-4295(97)00238-0 · Cited by 5,849
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686
Cited by
Emerging Strategies of Nanomaterial‐Mediated Tumor Radiosensitization
Xie, J., Gong, L., Zhu, S., Yong, Y., Gu, Z., & Zhao, Y. (2019) · Advanced Materials · doi:10.1002/adma.201802244 · Cited by 415
Metadata
- Authors
- Zaorsky, N. G., Davis, B. J., Nguyen, P. L., Showalter, T. N., Hoskin, P. J., Yoshioka, Y., Morton, G. C., & Horwitz, E. M.
- Venue
- Nature Reviews Urology
- Published
- 2017-06-30
- Volume
- 14
- Issue
- 7
- Pages
- 415-439
- ISSN
- 1759-4812 (ISSN-L)
- 1759-4820
- OpenAlex
- W2729996436
- Cited by
- 175
- References
- 2
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The evolution of brachytherapy for prostate cancer. https://app.cochat.ai/papers/10.1038/nrurol.2017.76
- The paper
- Zaorsky, N. G., Davis, B. J., Nguyen, P. L., Showalter, T. N., Hoskin, P. J., Yoshioka, Y., Morton, G. C., & Horwitz, E. M. (2017). The evolution of brachytherapy for prostate cancer. Nature Reviews Urology. https://doi.org/10.1038/nrurol.2017.76
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.